November 6, 2014
Bayer Healthcare has resumed production of Xofigo® (radium Ra 223 dichloride). The initial lot of Xofigo has been released and is available to begin patient treatment this week.
In addition to the letter, Bayer shared an updated Q&A for prostate cancer patients receiving Xofigo therapy, including when therapy can be rescheduled, the impact of missed doses, and more about the problem that halted production.
Healthcare professionals and patients who have questions should contact Bayer Medical Affairs at 888-84-BAYER (1-888-842-2937).
November 11 Update: Bayer announced today that production of Xofigo for new patients will resume on Monday, November 17.